Literature DB >> 17692633

First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis.

G Vennarecci1, G M Ettorre, M Antonini, R Santoro, M Maritti, G Tacconi, D Spoletini, L Tessitore, L Perracchio, G Visco, C Puoti, E Santoro.   

Abstract

AIM: The present study focused on nine patients with hepatocellular carcinoma (HCC) associated with Child A liver cirrhosis undergoing first-line liver resection and salvage liver transplantation (SLT) for liver tumor recurrence. PATIENTS AND METHODS: Forty-six patients with HCC underwent liver transplantation (OLT); 37 (80.5%) were primary liver transplantations (PLTs) and 9 (19.5%) were SLTs. All patients who underwent SLT received minor transabdominal liver resections.
RESULTS: The posttransplant 1-, 3-, and 5-year overall survival rates for SLT (88.9%, 88.9%, and 88.9%) were similar to those for PLT (78%, 62.7%, and 62.7%). Four (10.8%) patients in the PLT group had HCC recurrence, while there was zero recurrence in the SLT group. The 1-, 3-, 5-year disease-free survival rates for PLT (89%, 74%, and 74%) were similar to those for SLT (100%, 100%, and 100%). The 1-, 3-, 5-year disease-free survival rates after PLT were 89%, 74%, and 74%, and after SLT were 100%, 100%, and 100%, respectively. The operative mortality, intraperioperative bleeding, operative time, intensive care unit stay, in-hospital stay, and overall incidence of postoperative complications were similar in the two groups.
CONCLUSIONS: In our experience, SLT for HCC is a feasible procedure with similar results in terms of overall survival, disease-free survival, and postoperative complications to those reported for patients who underwent PLT at our institute. An important role exists for SLT as shown by the fact that such a strategy has been used in the 20% of the patients undergoing OLT for HCC.

Entities:  

Mesh:

Year:  2007        PMID: 17692633     DOI: 10.1016/j.transproceed.2007.05.073

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

Review 1.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Treatment algorithms for managing hepatocellular carcinoma.

Authors:  Vivek A Saraswat; Gaurav Pandey; Sachin Shetty
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

Review 3.  Current opinion on the role of resection and liver transplantation for hepatocellular cancer.

Authors:  P Puneet; M T P R Perera; Darius F Mirza
Journal:  Indian J Gastroenterol       Date:  2012-06-19

4.  Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis.

Authors:  Hong-Yu Li; Yong-Gang Wei; Lv-Nan Yan; Bo Li
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 5.  Advances in managing hepatocellular carcinoma.

Authors:  Marielle Reataza; David K Imagawa
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

Review 6.  Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis.

Authors:  Gian Piero Guerrini; Giuseppe Esposito; Tiziana Olivieri; Paolo Magistri; Roberto Ballarin; Stefano Di Sandro; Fabrizio Di Benedetto
Journal:  Cancers (Basel)       Date:  2022-07-16       Impact factor: 6.575

Review 7.  Current status of multimodal & combination therapy for hepatocellular carcinoma.

Authors:  Jian Yang; Lunan Yan; Wentao Wang
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

8.  Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection.

Authors:  Zhenhua Hu; Jie Zhou; Xiaofeng Xu; Zhiwei Li; Lin Zhou; Jian Wu; Min Zhang; Shusen Zheng
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

9.  Salvage Liver Transplant versus Primary Liver Transplant for Patients with Hepatocellular Carcinoma.

Authors:  Dipesh Kumar Yadav; Wei Chen; Xueli Bai; Alina Singh; Guogang Li; Tao Ma; Xiazhen Yu; Zhi Xiao; Bingfeng Huang; Tingbo Liang
Journal:  Ann Transplant       Date:  2018-08-03       Impact factor: 1.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.